Seeking Alpha

Cubist Pharmaceuticals (CBST -3%) slips on a mixed Q3 report yesterday, beating on its EPS but...

Cubist Pharmaceuticals (CBST -3%) slips on a mixed Q3 report yesterday, beating on its EPS but missing on revenue estimates. Net earnings rose 66% Y/Y as the company continued to see strong growth for its intravenous antibiotic Cubicin, but it also cut guidance going forward. The bio-pharmaceutical developer now sees revenue in the range of $915M - $931M, below Street estimates of $931M.

Check out Seeking Alpha’s new Earnings Center »

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs